Syneron Medical Ltd.  

(Public, NASDAQ:ELOS)   Watch this stock  
Find more results for ELOS
8.91
+0.11 (1.25%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.81 - 9.13
52 week 7.21 - 11.15
Open 8.81
Vol / Avg. 102,127.00/144,181.00
Mkt cap 315.48M
P/E     -
Div/yield     -
EPS -0.04
Shares 35.41M
Beta 1.54
Inst. own 71%
May 22, 2013
Q1 2013 Syneron Medical Ltd Earnings Conference Call - 8:30AM EDT - Add to calendar
May 6, 2013
Q1 2013 Syneron Medical Ltd Earnings Release
Apr 17, 2013
Syneron Medical Ltd Management Transition Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 6.81% -0.89%
Operating margin -2.34% -2.95%
EBITD margin - 3.68%
Return on average assets 6.33% -0.73%
Return on average equity 9.47% -0.59%
Employees 605 -
Carbon Disclosure Rating - -

Address

Tavor Building 4, Industrial Zone P.O. Box 550
YOKNEAM, 20692
Israel
+972-4-9096200 (Phone)
+972-4-9096202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Syneron Medical Ltd., designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company�s products, which it sells primarily to physicians and other practitioners, target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin�s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference and laser-assisted lipolysis. On February 13, 2012, the Company acquired Ultrashape Ltd. On March 14, 2012, Syneron acquired substantially all the assets of TransPharma Medical Ltd.

Officers and directors

Shimon Eckhouse Ph.D. Chairman of the Board, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Hugo Goldman Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Dominick A. Arena Director
Age: 70
Bio & Compensation  - Reuters
Michael J. Anghel External Independent Director
Age: 74
Bio & Compensation  - Reuters
Yaffa Krindel Independent Director
Age: 58
Bio & Compensation  - Reuters
David Schlachet Independent Director
Age: 67
Bio & Compensation  - Reuters
Dan S. Suesskind External Independent Director
Age: 69
Bio & Compensation  - Reuters